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Abstract: Appropriate control of blood pressure (BP) in hypertensive patients still represents 
the major therapeutic goal in the treatment of hypertension. Despite the growing attention and 
wide range of antihypertensive agents available in the clinical scenario, the target of BP below 
the advised thresholds of 140/90 mmHg is, unfortunately, often unreached. For this reason, the 
search for new antihypertensive agents is still ongoing. Azilsartan medoxomil, a new angio-
tensin receptor blocker that has been recently introduced in the clinical arena, represents the 
eighth angiotensin receptor blocker currently available for BP control. The aim of this paper 
is to describe the efficacy and safety profile of this new compound, reviewing available data 
obtained from both pre-clinical and clinical studies.
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Introduction
Chronically elevated blood pressure (BP) is a highly heterogeneous, complex disease 
and a major global health issue.1 Hypertension affects approximately one quarter of 
the world’s adult population, and is predicted to increase in prevalence alongside 
the urbanization of economically developing countries.2,3 Hypertension has been 
  recognized by the World Health Organization as the leading cause of global mortality, 
accounting for 7.6 million deaths and 92 million disability-adjusted life-years 
worldwide.4,5 Such sinister statistics are reflected in cardiovascular data showing that 
two-thirds of all cerebrovascular disease cases and 50% of all ischemic heart disease 
cases are attributable to non-optimal BP.5,6
Among  the  many  antihypertensive  agents,  drugs  that  modulate  the 
renin-angiotensin-aldosterone system (RAAS) are more commonly used because of their 
efficacy and their excellent tolerability profile. Specifically, those agents able to inhibit the 
action of angiotensin II by binding directly to the angiotensin type 1 (AT1) receptor, such 
as angiotensin receptor blockers (ARBs), are the most tolerated.7 In addition, aside from 
their well-known renoprotective effects,8,9 some ARBs have shown efficacy in reducing 
mortality in patients with heart failure and post-myocardial infarction.10–12
For these reasons, the search for novel antihypertensive agents – a novel ARB in 
particular – is still ongoing. The aim of this review is to focus attention on a novel 
ARB recently introduced in the clinical arena: azilsartan medoxomil.
Why and how we need to target the RAAS system
The pathophysiology of essential hypertension is complex and, although genome-
wide association studies have delineated multiple common variants associated 
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with essential hypertension, no firm hypothesis has yet 
been established.13 Multiple signaling pathways regulating 
BP have previously been elicited through physiological 
experiments. Of these, the discovery and accurate 
characterization of the neurohumoral pathway of the 
RAAS has enabled the production of pharmacological 
agents that assist in reducing a patient’s BP.14 Figure 1 
recapitulates the RAAS. Briefly, the RAAS cascade 
converts angiotensinogen to angiotensin II through an 
intermediate substrate, angiotensin I. The rate-limiting step 
within the cascade requires renin, a hormone synthesized 
and released from juxtaglomerular cells within the 
kidney’s afferent arterioles, to convert angiotensinogen to 
angiotensin I.14 Angiotensin I is then enzymatically converted 
into angiotensin II, a pleiotropic hormone able to target 
the angiotensin type 1 receptor (AT1R), which is located 
throughout the vasculature of multiple organs.14 Angiotensin 
II causes systemic vasoconstriction, increased sympathetic 
output, increased arginine vasopressin production, and 
increased aldosterone release. Consequently, an increase 
in angiotensin II results in increased peripheral vascular 
resistance, fluid retention, and increased cardiac output, 
thus contributing to elevated BP.
The conversion of angiotensin I to angiotensin II is 
  mediated by the angiotensin converting enzyme (ACE). 
Competitive inhibition of the ACE, a relatively non-  specific 
enzyme, with ACE inhibitors can assist in reducing BP. Meta-
analysis demonstrated a reduction in both systolic and dia-
stolic pressures in patients with essential hypertension, with 
a mean reduction of 6–9 mmHg and a 4–5 mmHg, respec-
tively.15 Despite these advantages, some limitations exist 
relating to ACE inhibitors. On one hand, substrate accumu-
lation of renin and angiotensin I may attenuate the desired 
blockade. On the other hand, concomitant tachykinin 
accumulation frequently incites side effects, including dry 
cough and angioedema, thus reducing the compliance of 
the patient with respect to its prescribed regimen, which 
in turn contributes to sub-optimal BP control. In addition, 
angiotensin II formation is not entirely dependent upon 
the action of the ACE, with formation occurring through 
alternative pathways.
To overcome the limitations of ACE inhibitors, the 
strategy to directly inhibit the binding of angiotensin II 
to the AT1R through ARBs has been shown to provide an 
effective pharmacologic strategy for inhibiting the AT1R 
and diminishing angiotensin II-derived effects, through 
both ACE-dependent and alternate pathways.14 Eight ARBs 
(losartan, valsartan, candesartan, irbesartan, olmesartan, 
telmisartan, eprosartan, and azilsartan) have been approved 
for the treatment of hypertension. Their main characteristics 
are summarized in Table 1. Clinically, ACE inhibitors and 
ARBs are prescribed interchangeably for the first-line treat-
ment of hypertension.16
In addition to ACE inhibitors and ARBs, there is an 
increasing number of additional agents, which modulate 
the RAAS, to lower BP and prevent cardiovascular events, 
including aldosterone antagonists, renin inhibitors, and 
neutral endopeptidase inhibitors.17–19 As this specific review 
will focus on azilsartan medoxomil, we refer the reader to 
specifically focused articles.20–24
Angiotensinogen
Ang I
Ang II
AT2R AT1R
Renin
ACE
ACE
inhibitors
Direct renin 
inhibitors
ARBs
Aldosterone
Aldosterone
receptor 
antagonists
Bradykinin Inactive
fragments 
Alternative
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Figure 1 The renin-angiotensin-aldosterone system.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
300
De Caterina et alVascular Health and Risk Management 2012:8
T
a
b
l
e
 
1
 
C
o
m
p
a
r
i
s
o
n
 
o
f
 
t
h
e
 
e
i
g
h
t
 
c
u
r
r
e
n
t
l
y
 
a
v
a
i
l
a
b
l
e
 
a
n
g
i
o
t
e
n
s
i
n
-
r
e
c
e
p
t
o
r
 
b
l
o
c
k
e
r
s
G
e
n
e
r
i
c
 
 
n
a
m
e
B
r
a
n
d
 
n
a
m
e
D
o
s
e
 
(
m
g
)
C
o
s
t
 
 
(
2
8
-
t
a
b
 
p
a
c
k
)
M
e
t
a
b
o
l
i
s
m
H
a
l
f
-
l
i
f
e
 
 
(
h
)
P
r
i
m
a
r
y
 
 
f
u
n
c
t
i
o
n
D
o
s
i
n
g
A
T
1
/
A
T
2
 
r
e
c
e
p
t
o
r
 
s
e
l
e
c
t
i
v
i
t
y
P
r
e
s
s
o
r
 
i
n
h
i
b
i
t
i
o
n
 
 
a
t
 
2
4
 
h
o
u
r
s
A
z
i
l
s
a
r
t
a
n
E
d
a
r
b
i
 
(
T
a
k
e
d
a
)
4
0
 
8
0
£
5
4
.
1
9
 
£
5
4
.
1
9
H
e
p
a
t
i
c
:
 
m
a
i
n
l
y
 
 
C
Y
P
2
C
9
 
(
a
l
s
o
 
C
Y
P
2
B
6
 
 
a
n
d
 
C
Y
P
2
C
8
)
;
 
n
o
 
 
C
Y
P
 
i
n
h
i
b
i
t
i
o
n
;
 
 
i
n
h
i
b
i
t
s
 
p
-
g
l
y
c
o
p
r
o
t
e
i
n
1
1
H
y
p
e
r
t
e
n
s
i
o
n
8
0
 
m
g
 
o
n
c
e
 
d
a
i
l
y
 
 
f
o
r
 
h
y
p
e
r
t
e
n
s
i
o
n
.
1
0
,
0
0
0
-
f
o
l
d
3
2
 
m
g
 
6
0
%
C
a
n
d
e
s
a
r
t
a
n
A
t
a
c
a
n
d
4
3
2
£
9
.
7
8
£
1
6
.
1
3
E
s
t
e
r
 
h
y
d
r
o
l
y
s
i
s
 
w
i
t
h
i
n
 
 
g
a
s
t
r
o
i
n
t
e
s
t
i
n
a
l
 
w
a
l
l
9
H
y
p
e
r
t
e
n
s
i
o
n
,
 
 
h
e
a
r
t
 
f
a
i
l
u
r
e
8
–
3
2
 
m
g
 
o
n
c
e
 
d
a
i
l
y
 
o
v
e
r
 
 
4
-
(
f
o
r
 
h
y
p
e
r
t
e
n
s
i
o
n
)
 
o
r
 
 
2
-
(
f
o
r
 
h
e
a
r
t
 
f
a
i
l
u
r
e
)
 
 
w
e
e
k
 
i
n
t
e
r
v
a
l
s
.
1
0
,
0
0
0
-
f
o
l
d
8
 
m
g
 
5
0
%
E
p
r
o
s
a
r
t
a
n
T
e
v
e
t
e
n
3
0
0
 
6
0
0
£
7
.
3
1
 
£
1
4
.
3
1
N
o
t
 
m
e
t
a
b
o
l
i
z
e
d
 
a
n
d
 
 
e
l
i
m
i
n
a
t
e
d
 
u
n
c
h
a
n
g
e
d
2
0
H
y
p
e
r
t
e
n
s
i
o
n
4
0
0
–
8
0
0
 
m
g
 
 
o
n
c
e
 
d
a
i
l
y
,
 
i
n
c
r
e
a
s
e
 
 
a
f
t
e
r
 
2
–
3
 
w
e
e
k
s
1
0
0
0
-
f
o
l
d
3
5
0
 
m
g
 
3
0
%
I
r
b
e
s
a
r
t
a
n
A
p
r
o
v
e
l
 
(
B
r
i
s
t
o
l
-
 
M
y
e
r
s
 
S
q
u
i
b
b
)
 
 
(
S
a
n
o
fi
-
A
v
e
n
t
i
s
)
7
5
 
3
0
0
£
9
.
6
9
 
£
1
5
.
9
3
H
e
p
a
t
i
c
:
 
g
l
u
c
u
r
o
n
i
d
a
t
i
o
n
 
 
a
n
d
 
o
x
i
d
a
t
i
o
n
 
b
y
 
C
Y
P
2
C
9
1
1
–
1
5
H
y
p
e
r
t
e
n
s
i
o
n
,
 
d
i
a
b
e
t
i
c
 
 
n
e
p
h
r
o
p
a
t
h
y
1
5
0
–
3
0
0
 
m
g
 
o
n
c
e
 
d
a
i
l
y
 
 
f
o
r
 
h
y
p
e
r
t
e
n
s
i
o
n
 
a
n
d
 
r
e
n
a
l
 
 
d
i
s
e
a
s
e
 
i
n
 
h
y
p
e
r
t
e
n
s
i
v
e
 
 
t
y
p
e
 
2
 
d
i
a
b
e
t
e
s
 
m
e
l
l
i
t
u
s
.
8
5
0
0
-
f
o
l
d
1
5
0
 
m
g
 
4
0
%
 
3
0
0
 
m
g
 
6
0
%
L
o
s
a
r
t
a
n
L
o
s
a
r
t
a
n
 
 
P
o
t
a
s
s
i
u
m
,
 
 
C
o
z
a
a
r
2
5
 
 
1
0
0
£
1
.
4
5
 
£
1
6
.
1
8
 
£
1
.
4
7
 
£
1
6
.
1
8
H
e
p
a
t
i
c
:
 
C
Y
P
2
C
9
 
a
n
d
 
 
C
Y
P
3
A
4
2
H
y
p
e
r
t
e
n
s
i
o
n
,
 
 
d
i
a
b
e
t
i
c
 
 
n
e
p
h
r
o
p
a
t
h
y
2
5
–
1
0
0
 
m
g
 
o
n
c
e
 
d
a
i
l
y
 
 
o
v
e
r
 
s
e
v
e
r
a
l
 
w
e
e
k
s
 
 
f
o
r
 
h
y
p
e
r
t
e
n
s
i
o
n
 
a
n
d
 
 
d
i
a
b
e
t
i
c
 
n
e
p
h
r
o
p
a
t
h
y
;
 
1
2
.
5
–
1
5
0
 
m
g
 
o
n
c
e
 
d
a
i
l
y
 
 
o
v
e
r
 
w
e
e
k
l
y
 
i
n
t
e
r
v
a
l
s
 
 
f
o
r
 
c
h
r
o
n
i
c
 
h
e
a
r
t
 
f
a
i
l
u
r
e
1
0
0
0
-
f
o
l
d
1
0
0
 
m
g
 
2
5
%
–
4
0
%
O
l
m
e
s
a
r
t
a
n
O
l
m
e
t
e
c
2
0
 
4
0
£
1
2
.
9
5
 
£
1
7
.
5
0
E
s
t
e
r
 
h
y
d
r
o
l
y
s
i
s
 
w
i
t
h
i
n
 
 
g
a
s
t
r
o
i
n
t
e
s
t
i
n
a
l
 
w
a
l
l
1
3
H
y
p
e
r
t
e
n
s
i
o
n
1
0
–
4
0
 
m
g
 
o
n
c
e
 
d
a
i
l
y
 
 
f
o
r
 
h
y
p
e
r
t
e
n
s
i
o
n
.
1
2
,
5
0
0
-
f
o
l
d
2
0
 
m
g
 
6
1
%
 
4
0
 
m
g
 
7
4
%
T
e
l
m
i
s
a
r
t
a
n
 
M
i
c
a
r
d
i
s
 
(
B
o
e
h
r
i
n
g
e
r
 
 
I
n
g
e
l
h
e
i
m
)
4
0
 
8
0
£
8
.
0
0
 
£
1
7
.
0
0
M
i
n
i
m
a
l
l
y
 
c
o
n
j
u
g
a
t
e
d
,
 
 
n
o
 
C
Y
P
4
5
0
 
a
c
t
i
v
a
t
i
o
n
2
4
H
y
p
e
r
t
e
n
s
i
o
n
4
0
–
8
0
 
m
g
 
o
n
c
e
 
d
a
i
l
y
 
a
f
t
e
r
 
 
4
 
w
e
e
k
s
 
f
o
r
 
h
y
p
e
r
t
e
n
s
i
o
n
;
 
 
8
0
 
m
g
 
o
n
c
e
 
d
a
i
l
y
 
t
o
 
p
r
e
v
e
n
t
 
 
c
a
r
d
i
o
v
a
s
c
u
l
a
r
 
e
v
e
n
t
s
.
3
0
0
0
-
f
o
l
d
8
0
 
m
g
 
4
0
%
V
a
l
s
a
r
t
a
n
D
i
o
v
a
n
 
(
N
o
v
a
r
t
i
s
)
4
0
 
1
6
0
£
1
3
.
9
7
 
£
1
8
.
4
1
M
i
n
i
m
a
l
 
m
e
t
a
b
o
l
i
s
m
 
 
(
C
Y
P
2
C
9
)
 
a
n
d
 
e
l
i
m
i
n
a
t
e
d
 
 
l
a
r
g
e
l
y
 
u
n
c
h
a
n
g
e
d
6
H
y
p
e
r
t
e
n
s
i
o
n
,
 
 
h
e
a
r
t
 
f
a
i
l
u
r
e
,
 
 
m
y
o
c
a
r
d
i
a
l
 
i
n
f
a
r
c
t
i
o
n
8
0
–
3
2
0
 
m
g
 
o
n
c
e
 
d
a
i
l
y
 
 
o
v
e
r
 
4
 
w
e
e
k
s
 
f
o
r
 
 
h
y
p
e
r
t
e
n
s
i
o
n
;
 
4
0
 
m
g
 
t
w
i
c
e
 
d
a
i
l
y
,
 
u
p
 
t
o
 
1
6
0
 
m
g
 
 
t
w
i
c
e
 
d
a
i
l
y
,
 
o
v
e
r
 
2
-
w
e
e
k
 
 
i
n
t
e
r
v
a
l
s
 
f
o
r
 
h
e
a
r
t
 
f
a
i
l
u
r
e
;
 
2
0
 
m
g
 
t
w
i
c
e
 
d
a
i
l
y
,
 
u
p
 
t
o
 
 
1
6
0
 
m
g
 
t
w
i
c
e
 
d
a
i
l
y
,
 
o
v
e
r
 
 
2
-
w
e
e
k
 
i
n
t
e
r
v
a
l
s
 
f
o
r
 
 
m
y
o
c
a
r
d
i
a
l
 
i
n
f
a
r
c
t
i
o
n
2
0
,
0
0
0
-
f
o
l
d
8
0
 
m
g
 
3
0
%
N
o
t
e
s
:
 
D
a
t
a
 
d
r
a
w
n
 
f
r
o
m
 
Z
a
i
k
e
n
 
K
,
 
C
h
e
n
g
 
J
w
.
 
A
z
i
l
s
a
r
t
a
n
 
m
e
d
o
x
o
m
i
l
:
 
a
 
n
e
w
 
a
n
g
i
o
t
e
n
s
i
n
 
r
e
c
e
p
t
o
r
 
b
l
o
c
k
e
r
.
 
C
l
i
n
 
T
h
e
r
.
 
2
0
1
1
;
3
3
(
1
1
)
:
1
5
7
7
–
1
5
8
9
.
2
3
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
301
Critical evaluation of azilsartanVascular Health and Risk Management 2012:8
Azilsartan medoxomil: 
pharmacodynamic and 
pharmacokinetic profile
Following the introduction in the clinical arena of azilsartan 
medoxomil in early 2011, eight ARBs are now   recognized 
in Europe and by the United States Food and Drug 
Administration for the treatment of hypertension.
Mechanism of action
Azilsartan medoxomil (previously named TAK-491), an 
orally administered prodrug, has recently become the eighth 
ARB to achieve Food and Drug Administration approval for 
the treatment of hypertension. Following oral administration, 
azilsartan medoxomil is hydrolyzed into azilsartan (TAK-536) 
in both the gastrointestinal tract and plasma.25   Azilsartan, 
a selective AT1R antagonist, prevents angiotensin II binding, 
specifically within vascular, smooth muscles and the adrenal 
gland, and produces vasodilation and attenuated aldosterone 
effects.26 Azilsartan and candesartan are structurally very 
similar, which may explain their similar AT1R affinity. Indeed, 
azilsartan is a highly selective antagonist for AT1R, exhibiting 
a .10,000-fold higher affinity for the AT1 receptor than for the 
AT2 receptor.24 This effect is significant; however, valsartan, 
olmesartan, and candesartan all demonstrate equivalent 
or greater AT1 selectivity (see Table 1). The manufacturer 
suggests that the antihypertensive effect of azilsartan is not 
disrupted by renin secretion fluctuations, primarily due to its 
AT1R inhibition.26
Pharmacokinetics
Azilsartan achieves its peak plasma concentration 1.5 to 
3 hours following oral administration, with bioavailability 
(approximately 58%) unaffected by co-administration with food. 
Azilsartan demonstrates a half-life of approximately 11 hours 
and achieves a steady-state concentration 5 days   following 
  consecutive oral administration.25,26 Reports from healthy 
subjects suggest that the volume of distribution is approximately 
30 L, with .99% circulating attached to plasma proteins.25,26
Azilsartan metabolism occurs mainly via the hepatic cyto-
chrome P450, with no CYP system induction or inhibition 
properties. Azilsartan does, however, inhibit p-glycoprotein, 
an efflux transporter. A major inactive metabolite (MI) 
forms through CYP2C9, while an additional minor, inactive 
metabolite (MII) is generated through CYP2B6 and CYP2C8. 
The MII has approximately 50% systemic exposure, and MI 
has ,1% systemic exposure.21,23
Azilsartan’s inactive metabolites (MI and MII) are 
excreted by the kidney at a rate of 2.3 mL/min. Animal studies 
recording 14C-radiolabeled orally administered azilsartan 
recovered approximately 97% of the administered dose 
within 14 days. Specifically, 55% was traced to fecal 
excretion, and urine accounted for 42%, of which 15% was 
excreted as azilsartan.23
Although no studies regarding the pharmacokinetics of 
azilsartan are currently available on the PubMed website, 
the manufacturer has made available data reporting a dose 
proportionality following single- and multiple-dosing of azil-
sartan in the dose range of 20–320 mg. According to single- 
and multiple-dose pharmacokinetic studies, AUC and Cmax 
are both modestly affected by age, sex, race, renal impairment 
(mild, moderate, severe, or end-stage renal disease), and 
hepatic impairment, although the pharmacokinetic properties 
of azilsartan have not been studied in patients with severe 
hepatic impairment. Accordingly, no dosage adjustment of 
azilsartan is suggested on the basis of a patient’s age, gender, 
race, or degree of renal/hepatic impairment.25
As with current ARBs, it is inadvisable to prescribe 
azilsartan during the first, second, or third trimesters of 
pregnancy. Although human studies have not been conducted, 
evidence has been gleaned from low levels of azilsartan being 
detected in lactating rats’ milk.
Drug interactions
No major drug interaction studies on azilsartan have been 
reported to date; however, the manufacturer reports no sig-
nificant pharmacokinetic disruptions for numerous drugs 
combined with either 40-mg or 80-mg doses of azilsartan. 
Drug interactions with a daily 80-mg azilsartan dose were 
investigated in 36 healthy volunteers against concomitant 
administration of a P450 probe cocktail (including 30 mg 
of dextromethorphan, 500 mg of tolbutamide, 200 mg of 
caffeine, 4 mg of midazolam, and 60 mg of fexofenadine) or 
coadministration with an antacid or oral digoxin.25 Similarly, 
an orally administered 40 mg dose of azilsartan was investi-
gated in 36 healthy volunteers, with concomitant delivery of 
warfarin, glyburide, metformin pioglitazone, chlorthalidone, 
and amlodipine. No significant pharmacokinetic or interna-
tional normalized ratio differences were in evidence.25
In addition, 36 healthy volunteers undertook a drug 
interaction study investigating 40 mg doses of azilsartan 
with co-administration of either 200 mg of fluconazole 
(a  CYP2C9  inhibitor)  or  400  mg  of  ketoconazole 
(a CYP3A4/5 inhibitor). The study described how concomitant 
CYP2C9 inhibition causes reduced renal clearance and 
increased the AUC by approximately 40%.25 Concomitant 
CYP3A4/5 inhibition reduced the AUC by approximately 20%. 
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This initial study requires further investigation to fully evaluate 
the true clinical significance of this interaction.
Although no evidence specifically evaluating azil-
sartan with nonsteroidal anti-inflammatory agents or 
cyclooxygenase-2 inhibitors exists, Takeda issued a 
warning about their combined usage with azilsartan.26 This 
concern stems from knowledge regarding non-steroidal 
anti-inflammatory agents and cyclooxygenase-2 inhibitors 
contributing to acute pre-renal failure through prostaglandins 
inhibition and a reduced glomerular filtration rate.
Preclinical trials
Preclinical studies have demonstrated that azilsartan is 
superior to alternative ARBs (ie, valsartan and olmesartan) 
in lowering 24-hour BP. Current evidence suggests that this 
response is due to its property of high affinity and slow dis-
sociation to AT1R. This characteristic attenuates angiotensin 
II-derived effects more persistently than previous ARBs, 
leading to a prolonged functional effect.24,27
Aside from blocking AT1R, ARBs have been shown to 
provide additional benefits in cardiovascular protection, and 
preclinical studies have investigated the pleiotropic effects of 
this new compound, in addition to BP control. Many of the 
functional effects demonstrated by azilsartan are dependent 
on two key factors relating to the molecule: its high affinity 
and slow dissociation from AT1R, and its inverse agonistic 
properties. These factors make azilsartan a unique option as 
a possible therapeutic agent in a wide range of angiotensin 
II-dependent cardiometabolic diseases. These include cardiac 
hypertrophy, unstable atherosclerotic plaque, cardiac fibrosis, 
insulin resistance, and renoprotection.
Several studies have investigated the anti-  proliferative 
properties of azilsartan within vascular endothelial 
cells compared to traditional ARBs. Azilsartan has been 
shown to be superior in inhibiting the proliferation of rabbit 
aortic endothelial cells compared to valsartan. Interestingly, 
the anti-proliferative properties demonstrated by azilsartan 
can be established at plasma concentrations of 1 µmol/L, 
similar to human oral drug-dosing concentrations.24 The 
mechanism attenuating proliferation is not entirely AT1R-
dependent, and it has been suggested that the pleiotropic 
effects are largely attributable to azilsartan’s inverse agonist 
properties. These inverse agonist properties are clinically 
relevant, as they could enable a new generation of ARBs, 
including azilsartan, to prevent cardiac hypertrophy.
Investigators have also demonstrated that azilsartan 
can stabilize atherosclerotic plaque and reduce cardiac 
fibrosis formation following myocardial infarction in mice. 
  Specifically, it has been proposed that azilsartan suppresses 
the angiotensin II-mediated plasminogen activator inhibitor 
type-1, causing increased collagen deposition, thus stabiliz-
ing atherosclerotic plaque.28
Hypertension is associated with insulin resistance, pos-
sibly due to excess angiotensin II. Candesartan has previously 
demonstrated improved insulin sensitivity in hypertensive 
patients.29 Investigators have determined that azilsartan also 
demonstrates improved insulin sensitivity in rats, mice, and 
dogs in a superior fashion to olmesartan.30,31 Debates continue, 
however, regarding how ARBs generate this effect.
Finally, patients with metabolic syndrome have a poorer 
prognosis if there is documented proteinuria.32,33 Traditional 
ARBs have previously been shown to benefit the diabetic 
population, mainly offering a renoprotective effect related to 
a reduction of proteinuria.10 Azilsartan has been investigated 
in animal models with nephropathy, and Kusumoto et al 
showed azilsartan to be superior in reducing albuminuria in 
rats compared to olmesartan.31
The results from these pre-clinical trials are encouraging; 
however, validation and replication in humans is required. 
Azilsartan has demonstrates superior 24-hour control of 
systolic BP and offers a broad spectrum of possible clinical 
benefits associated with cardiometabolic disease, possibly 
making it superior to traditional ARBs.
Clinical trials
Several comparative studies have assessed the efficacy of 
azilsartan in the treatment of hypertension. In a double-blind, 
placebo-controlled trial of 1275 hypertensive patients, 
the efficacy of azilsartan was compared to placebo and 
  olmesartan. The primary efficacy measure was the mean 
24-hour ambulatory systolic pressure. The mean baseline 
  systolic BP was 146 mmHg. Eighty-mg doses of azilsartan 
were more effective in reducing the mean 24-hour   systolic 
  pressure compared to 40 mg of olmesartan (a mean difference 
of 2.1 mmHg). In terms of tolerability, azilsartan was very 
well tolerated, as the incidence of the most commonly 
reported adverse events (ie, headache, dyslipidemia, and 
dizziness) were reported to be similar compared to the 
placebo and candesartan groups.34
In another study of 1291 subjects, where the mean systolic 
BP before treatment was 145 mmHg, reduction was high-
est with 80 mg of azilsartan (−14.3 mmHg), compared to 
320 mg of valsartan (−10.0 mmHg) and 40 mg of olmesartan 
(−11.7 mmHg).35 BP control and response rates were higher 
than those observed in the valsartan arm, with an absolute rate 
of approximately 10% of patients reaching an acceptable BP 
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control according to actual guidelines. Again, the tolerability 
profile was not significantly different compared to 320 mg 
of valsartan, especially with regard to the number of adverse 
events, including those that were life-threatening or simply 
lead to a discontinuation of the drug.
The superiority of azilsartan was also confirmed 
when compared to other sartans. In a recently published 
study, 622 hypertensive Japanese patients with moderate 
hypertension were randomized for treatment with azilsartan 
(20–40 mg od) or candesartan (8–12 mg od). Azilsartan 
was more effective in reducing sitting systolic and diastolic 
BP at 16 weeks and ambulatory BP at 14 weeks, with a 
similar safety profile.22 The study concludes by stating that 
once-daily azilsartan use provides a more-potent, 24-hour 
antihypertensive effect than does candesartan, but with an 
equivalent safety threshold.
In summary, clinical trials of azilsartan have so far dem-
onstrated promising results, and this new substance has the 
potential to become a very valuable drug in the treatment of 
hypertension.
Conclusion
Azilsartan is a very recently approved ARB that is now 
available in the clinical arena for the treatment of hypertension. 
Compared to the maximum doses of three other ARBs (val-
sartan, olmesartan, and candesartan), azilsartan appears to be 
more efficacious in reducing BP, with a similar safety and 
tolerability profile. Azilsartan’s very high affinity and slow 
dissociation from AT1R, together with its inverse agonistic 
properties, make it a very attractive candidate for further 
pushing its clinical effects beyond simple BP   control, poten-
tially counteracting cardiac hypertrophy,   cardiac fibrosis, and 
insulin resistance, together with improved renoprotection and 
atherosclerotic plaque stabilization. However, unlike other 
ARBs, azilsartan is not backed up by clinical data supporting 
its ability to affect improvement in cardiovascular outcomes 
and is not approved for situations in which other ARBs may 
be used, such as diabetic nephropathy or heart failure.
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